335 related articles for article (PubMed ID: 37198624)
1. The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.
Hydes TJ; Kennedy OJ; Buchanan R; Cuthbertson DJ; Parkes J; Fraser SDS; Roderick P
BMC Med; 2023 May; 21(1):185. PubMed ID: 37198624
[TBL] [Abstract][Full Text] [Related]
2. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.
Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.
Wijarnpreecha K; Thongprayoon C; Scribani M; Ungprasert P; Cheungpasitporn W
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):404-410. PubMed ID: 29215435
[TBL] [Abstract][Full Text] [Related]
4. Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study.
Hara M; Tanaka S; Torisu K; Matsukuma Y; Tsuchimoto A; Tokumoto M; Ooboshi H; Nakano T; Tsuruya K; Kitazono T
Clin Exp Nephrol; 2021 Aug; 25(8):822-834. PubMed ID: 33856608
[TBL] [Abstract][Full Text] [Related]
5. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease.
Zuo G; Xuan L; Xin Z; Xu Y; Lu J; Chen Y; Dai M; Zhang D; Wang W; Li M; Bi Y; Ning G; Xu M
J Clin Endocrinol Metab; 2021 Sep; 106(10):e3957-e3968. PubMed ID: 34125886
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.
Chinnadurai R; Ritchie J; Green D; Kalra PA
Nephrol Dial Transplant; 2019 Mar; 34(3):449-457. PubMed ID: 29390103
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
8. Prognosis of chronic kidney disease in patients with non-alcoholic fatty liver disease: a Northeastern Taiwan community medicine research cohort.
Huang TS; Wu IW; Lin CL; Shyu YC; Chen YC; Chien RN
Biomed J; 2023 Apr; 46(2):100532. PubMed ID: 35460926
[TBL] [Abstract][Full Text] [Related]
9. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.
Baratta F; Pastori D; Angelico F; Balla A; Paganini AM; Cocomello N; Ferro D; Violi F; Sanyal AJ; Del Ben M
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2324-2331.e4. PubMed ID: 31887443
[TBL] [Abstract][Full Text] [Related]
10. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis.
Yan Z; Liu Y; Li W; Zhao X; Lin W; Zhang J; Yu S; Ma J; Wang J; Yu P; Li W; Liu X
Eur J Clin Invest; 2022 Nov; 52(11):e13855. PubMed ID: 36001034
[TBL] [Abstract][Full Text] [Related]
11. Systematic review of the impact of non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic kidney disease.
Hydes T; Buchanan R; Kennedy OJ; Fraser S; Parkes J; Roderick P
BMJ Open; 2020 Sep; 10(9):e040970. PubMed ID: 32988952
[TBL] [Abstract][Full Text] [Related]
12. Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants.
Chen S; Pang J; Huang R; Xue H; Chen X
Hepatol Int; 2023 Jun; 17(3):595-605. PubMed ID: 36809487
[TBL] [Abstract][Full Text] [Related]
13. Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk.
Delgado GE; Kleber ME; Moissl AP; Yazdani B; Kusnik A; Ebert MP; März W; Krämer BK; Lammert A; Teufel A
Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(4):G252-G261. PubMed ID: 34132110
[TBL] [Abstract][Full Text] [Related]
14. Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction.
Liu X; Chen W; Shao W; Jiang Y; Cao Z; He W; Wu M; Chen Z; Ma J; Chen Y; Yu P; Zhang Y; Wang J
ESC Heart Fail; 2022 Dec; 9(6):3985-3994. PubMed ID: 35996808
[TBL] [Abstract][Full Text] [Related]
15. Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Seo DH; Suh YJ; Cho Y; Ahn SH; Seo S; Hong S; Lee YH; Choi YJ; Lee E; Kim SH
Diabetes Metab J; 2022 Jul; 46(4):630-639. PubMed ID: 35081304
[TBL] [Abstract][Full Text] [Related]
16. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.
Yu X; Chen C; Guo Y; Tong Y; Zhao Y; Wu L; Sun X; Wu X; Song Z
Ann Med; 2021 Dec; 53(1):1621-1631. PubMed ID: 34498502
[TBL] [Abstract][Full Text] [Related]
17. Higher NAFLD fibrosis score is associated with impaired eGFR.
Hsieh MH; Wu KT; Chen YY; Yang JF; Lin WY; Chang NC; Lin CY; Huang CK; Wang CL; Chuang HY; Lin SC; Hsu YK; Tsai YS; Chuang WL; Yu ML; Dai CY
J Formos Med Assoc; 2020 Jan; 119(1 Pt 3):496-503. PubMed ID: 31353118
[TBL] [Abstract][Full Text] [Related]
18. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
Kim D; Kim WR; Kim HJ; Therneau TM
Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
[TBL] [Abstract][Full Text] [Related]
19. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
